4 documents found, page 1 of 1
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort
Casco, N; Jorge, AL; Palmero, DJ; Alffenaar, JW; Fox, GJ; Ezz, W; Cho, JG; Denholm, J; Skrahina, A; Solodovnikova, V; Arbex, MA; Alves, T; Rabahi, MFBackground Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes of patients affected by TB and COVID-19. Methods We collected data from 174 centres in 31 countries on all patients affected by COVID-19 and TB between 1 March 2020 and 30 September 2022. Patients were followed-up until cure, death or end...
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
Guenther, G; Leth, F; Alexandru, S; Altet, N; Avsar, K; Bang, D; Barbuta, R; Bothamley, G; Ciobanu, A; Crudu, V; Danilovits, M; Dedicoat, M; Duarte, RRationale: Multidrug-resistant tuberculosis (MDR-TB) is a major burden to public health in Europe. Reported treatment success rates are around 50% or less, and cure rates are even lower. Objectives: To document the management and treatment outcome in patients with MDR-TB in Europe. Methods: We performed a prospective cohort study, analyzing management and treatment outcomes stratified by incidence of patients w...
Treatment outcomes of MDR-TB and HIV co-infection in Europe
Magis-Escura, C; Günther, G; Lange, C; Alexandru, S; Altet, N; Avsar, K; Bang, D; Barbuta, R; Bothamley, G; Ciobanu, A; Crudu, V; Davilovits, M
Beyond multidrug-resistant tuberculosis in Europe: a TBNET study
Günther, G; van Leth, F; Altet, N; Dedicoat, M; Duarte, R; Gualano, G; Kunst, H; Muylle, I; Spinu, V; Tiberi, S; Viiklepp, P; Lange, CThe emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone an...